

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	1	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/512,067	10/21/2004		Ezio Bombardelli	2503-1114	8559
466	7590	11/14/2005		EXAMINER	
YOUNG &			WITHERSPOON, SIKARL A		
745 SOUTI 2ND FLOO		TREET	ART UNIT	PAPER NUMBER	
ARLINGTO	ON, VA	22202	1621		
				DATE MAILED: 11/14/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/512,067	BOMBARDELLI ET AL.				
Office Action Summary	Examiner	Art Unit				
	Sikarl A. Witherspoon	1621				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	 lely filed the mailing date of this communication. (35 U.S.C. § 133). 				
Status	•					
1)⊠ Responsive to communication(s) filed on <u>26 A</u>	<u>oril 2005</u> .					
2a) This action is FINAL . 2b) ☑ This	action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.				
Disposition of Claims						
 4) ☐ Claim(s) 1-9 is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-3,6 and 7 is/are rejected. 7) ☐ Claim(s) 4,5,8 and 9 is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or 						
Application Papers	, oleonor, roquirelline					
	<u>.</u>					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) □ acce		Examiner.				
Applicant may not request that any objection to the						
Replacement drawing sheet(s) including the correct						
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati ity documents have been receive I (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachment(s) 1) Notice of References Cited (PTO-892)	. 4) Interview Summary	(PTO-413)				
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 10/21/04. 	Paper No(s)/Mail Da					

Application/Control Number: 10/512,067

Art Unit: 1621

DETAILED ACTION

Claim Rejections - 35 USC § 102

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 1, 2, 6, and 7 are rejected under 35 U.S.C. 102(e) as being anticipated by Bombardelli et al (US 6,656,510). The reference discloses hyperforin acetate, said compound being useful as an antidepressant (col. 4, lines 15-20). This compound anticipates the instant claims.

The applied reference has a common inventor and assignee with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 102(e) might be overcome either by a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not the invention "by another," or by an appropriate showing under 37 CFR 1.131.

Claims 1-3 are rejected under 35 U.S.C. 102(a) as being anticipated by Chatterjee et al (US 6,322,824).

Application/Control Number: 10/512,067

Art Unit: 1621

The reference discloses the compound hyperforin useful in the treatment of dementia diseases, such as Alzheimer's disease. The compound disclosed by Chatterjee et al anticipates the instant claims.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1, 2, 6, and 7 are rejected under 35 U.S.C. 103(a) as being obvious over Bombardelli et al (US 6,656,510).

The applied reference has a common inventor and assignee with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art only under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 103(a) might be overcome by: (1) a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not an invention "by another"; (2) a showing of a date of invention for the claimed subject matter of the application which corresponds to subject matter disclosed but not claimed in the reference, prior to the effective U.S. filing date of the reference under 37 CFR 1.131; or (3) an oath or declaration under 37 CFR 1.130 stating that the application and reference are currently owned by the same party and that the inventor named in the application is the prior inventor under 35 U.S.C. 104, together with a terminal disclaimer

Application/Control Number: 10/512,067

Art Unit: 1621

in accordance with 37 CFR 1.321(c). This rejection might also be overcome by showing that the reference is disqualified under 35 U.S.C. 103(c) as prior art in a rejection under 35 U.S.C. 103(a). See MPEP § 706.02(l)(1) and § 706.02(l)(2). The reference discloses the compound hyperforin acetate (col. 4, lines 15-20), however no structure is disclosed. It is therefore assumed by the examiner that the compound may have specific stereochemistry, or is a racemic mixture of isomers. If the compound is a racemate, then it is obvious that the racemic mixture comprises a compound having the stereochemistry of the compound(s) of the instant invention, thereby rendering the instant claims obvious.

Claims 1-3 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chatterjee et al (US 6,322,824).

The reference discloses the compound hyperforin, said compound depicting no stereochemistry for the substituents, i.e., a racemic mixture of stereoisomers. It is obvious that the racemic mixture comprises a compound having the stereochemistry of the compound(s) of the instant invention, thereby rendering the instant claims obvious.

Claims 4, 5, 8 and 9 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

The examiner suggests that applicants amend claim 1 to read "A hyperforin or adhyperforin derivative..." and subsequent claims to read, "A derivative..."

Art Unit: 1621

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sikarl A. Witherspoon whose telephone number is 571-272-0649. The examiner can normally be reached on M-F 8:30-6:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

saw

SIKARL A. WITHERSPOON PATENT EXAMINER

Siken A. Witherpor